[Mitoxantrone (MTX) versus mitomycin C (MMC) in the ablative treatment of Ta, T1 superficial bladder tumors. Phase III, randomized prospective study].

@article{Torrent1992MitoxantroneV,
  title={[Mitoxantrone (MTX) versus mitomycin C (MMC) in the ablative treatment of Ta, T1 superficial bladder tumors. Phase III, randomized prospective study].},
  author={J V Ric{\'o}s Torrent and J L Monr{\'o}s Lliso and Inmaculada Iborra Juan and Juan Casanova Ram{\'o}n-Borja and R Dumont Mart{\'i}nez and Eduardo Solsona Narb{\'o}n},
  journal={Archivos espanoles de urologia},
  year={1992},
  volume={45 7},
  pages={647-52}
}
A prospective randomized study was conducted to determine the ablation capacity of mitoxantrone in Ta-T1 superficial bladder tumors versus mitomycin C, a drug whose intravesical ablation properties are well-known. Fifty-seven patients comprised the study. The tumor was not completely resected when the patient underwent TUR. This residual tumor was used as control. The patients were treated with either 20 mg Mitoxantrone or 40 mg mitomycin C weekly for 8 weeks and two other instillations every… CONTINUE READING